Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tamoxifen in Duchenne Muscular Dystrophy: A Multicenter, Randomised, Double-blind, Placebo-controlled, Phase 3 Safety and Efficacy 48-week Trial

NCT03354039 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT03354039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03354039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tamoxifen in Duchenne Muscular Dystrophy: A Multicenter, Randomised, Double-blind, Placebo-controlled, Phase 3 Safety and Efficacy 48-week Trial
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Phase 3
Overall status
Completed
Start date
June 12, 2018
Completion date
October 18, 2022
Enrollment
93 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy